News|Articles|November 20, 2026

Experts Tackle Key Questions on MAPK-Directed Therapy, Frontline PARP Inhibitor Maintenance, and ADCs in Ovarian Cancer

Author(s)OncLive Staff
Fact checked by: Chris Ryan

During a recent OncLive® State of the Science Summit™ on gynecologic oncology held on November 4, 2026, in Chicago, Illinois, chaired by Katherine Kurnit, MD, MPH, of the University of Chicago Medicine, faculty discussed ovarian cancer topics including current and emerging therapies in low-grade serous ovarian cancer, optimal treatment selection for PARP inhibitors, and antibody-drug conjugates as novel therapeutic strategies.

Related to this article